Treatment for hereditary blindness
Sparingvision has raised €135M across 3 funding rounds from 7 investors, most recently a Series B round in Sep 2022. Based in Paris, France; active in Healthtech. Data as of 6 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2022-09-14 | Series B | €75M | 4BIO Capital,Bpifrance,Jeito Capital,RD Fund,UPMC Enterprises,Ysios Capital | View deal → |
| 2020-10-21 | Other | €45M | 4BIO Capital,UPMC Enterprises | View deal → |
| 2017-07-07 | Other | €16M | Bpifrance,Fondation Fighting Blindness Clinical Research Institute | View deal → |
